New Anthropic Board Member Signals Healthcare Push - Forbes

Anthropic's Long-Term Benefit Trust (LTBT) has appointed Novartis CEO Vas Narasimhan as a new board member. The LTBT is a group of directors with no financial stake in Anthropic, designed to keep the company accountable to its mission of AI safety. This appointment pushes the number of Trust-appointed directors past 50% of the board.

The move signals Anthropic's intent to expand into healthcare applications for its AI models, such as Claude. Narasimhan's role as CEO of Novartis, a global pharmaceutical company, brings healthcare industry expertise to Anthropic's governance structure. The article frames this as part of a broader 'healthcare push' for the AI company.

Anthropic established the LTBT as a unique governance mechanism to align the company with long-term safety goals rather than shareholder returns. The Trust now holds a majority on the board, potentially influencing strategic decisions toward sectors like healthcare where AI deployment carries significant ethical and regulatory considerations.